Cardiac Toxicity Assessment Using Stem Cell Derived Cardiomyocytes

Posted by

ACEA Biosciences

Cardiac toxicity is a major hurdle in drug development. In this webinar Dr. Matthew F. Peters of AstraZeneca Pharmaceuticals (Boston, MA) discusses the utility of combining ACEA Bioscience’s xCELLigence® Cardio system with stem cell-derived cardiomyocytes for evaluating the cardiac risk of compounds. The xCELLigence® Cardio system is shown to provide a high throughput, quantitative and predictive assay that can be used early in the drug discovery process. Dr. Peters specifically addresses:

• Advancements in cellular impedance assays
• Drug screening applications utilizing cardiomyocyte cultures
• Cardiosafety attrition in comparison to other disease areas


Dr. Matthew F. Peters is a principal scientist at AstraZeneca Pharmaceuticals in Boston, MA. He has a long-standing interest in harnessing the sensitivity and versatility of label-free technology to address gaps in in vitro drug discovery screening. His initial work sought to develop assays capable of characterizing GPCR ligands with functional selectivity. More recently, he has focused on developing label-free impedance-based assays to address the dearth of early phase, high-throughput screens for cardiovascular function/toxicity. He was awarded his Ph.D. in physiology from the University of North Carolina for work developing a new model of the molecular organization of dystrophin complexes. Dr. Peters’ postdoctoral fellowship at Johns Hopkins University focused on elucidating the pathogenic mechanisms involved in Huntington’s disease.

For more information, please visit: http://www.aceabio.com/product/rtca-cardio/

REFERENCES:
1. Peters MF, Scott CW, Ochalski R, Dragan YP. Evaluation of cellular impedance measures of cardiomyocyte cultures for drug screening applications. Assay Drug Dev Technol. 2012 Dec;10(6):525-32.

2. Lamore SD, Kamendi HW, Scott CW, Dragan YP, Peters MF. Cellular impedance assays for predictive preclinical drug screening of kinase inhibitor cardiovascular toxicity. Toxicol Sci. 2013 Oct;135(2):402-13.

3. Scott CW, Zhang X, Abi-Gerges N, Lamore SD, Abassi YA, Peters MF. An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility. Toxicol Sci. 2014 Dec;142(2):331-8.

4. Peters MF, Lamore SD, Guo L, Scott CW, Kolaja KL. Human stem cell-derived cardiomyocytes in cellular impedance assays: bringing cardiotoxicity screening to the front line. Cardiovasc Toxicol. 2015 Apr;15(2):127-39.